Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB-ABDA Cause Dyspnoea? 145 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 145 reports of Dyspnoea have been filed in association with INFLIXIMAB-ABDA. This represents 8.0% of all adverse event reports for INFLIXIMAB-ABDA.

145
Reports of Dyspnoea with INFLIXIMAB-ABDA
8.0%
of all INFLIXIMAB-ABDA reports
0
Deaths
44
Hospitalizations

How Dangerous Is Dyspnoea From INFLIXIMAB-ABDA?

Of the 145 reports, 44 (30.3%) required hospitalization, and 11 (7.6%) were considered life-threatening.

Is Dyspnoea Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB-ABDA. However, 145 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB-ABDA Cause?

Off label use (493) Product use issue (272) Nausea (142) Crohn's disease (133) Arthralgia (131) Diarrhoea (118) Drug ineffective (111) Headache (111) Malaise (111) Abdominal pain (107)

What Other Drugs Cause Dyspnoea?

ALBUTEROL (21,856) TREPROSTINIL (16,348) AMBRISENTAN (13,367) PREDNISONE (12,830) BUDESONIDE\FORMOTEROL (11,158) TIOTROPIUM (10,863) ADALIMUMAB (10,547) DUPILUMAB (10,310) FLUTICASONE\SALMETEROL (9,783) MEPOLIZUMAB (9,192)

Which INFLIXIMAB-ABDA Alternatives Have Lower Dyspnoea Risk?

INFLIXIMAB-ABDA vs INFLIXIMAB-AXXQ INFLIXIMAB-ABDA vs INFLIXIMAB-DYYB INFLIXIMAB-ABDA vs INFLIXIMAB-QBTX INFLIXIMAB-ABDA vs INFLIXIMAB, RECOMBINANT INFLIXIMAB-ABDA vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN

Related Pages

INFLIXIMAB-ABDA Full Profile All Dyspnoea Reports All Drugs Causing Dyspnoea INFLIXIMAB-ABDA Demographics